NR4A1 and breast cancer: Triple negative (TN; negative for hormone receptors, And HER2 amplification/overexpression) and/or basal-like subtypes of breast cancer (BC) present the most challenging diagnosis among BC patients as it confers a poor clinical outcome due to (1) a diverse group of multiple genetic alterations in the refractory RD, (2) a frequent and an aggressive nature of metastasis, and (3) a limited number of available targeted therapeutic options owing to a poorly understood biology [1–3].